FindTrial
Sign In

Comparison the live birth rate between the early follicular phase ultra-long protocol and antagonist protocol in patients with normal ovarian response during in-vitro fertilization treatment: a single-center prospective open-label randomized controlled study

Comparison the live birth rate between the early follicular phase ultra-long protocol and antagonist protocol in patients with normal ovarian response during in-vitro fertilization treatment: a single-center prospective open-label randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800015574
Enrollment
Unknown
Registered
2018-04-08
Start date
2018-04-23
Completion date
Unknown
Last updated
2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility

Interventions

intervention group:early follicular phase ultra-long protocol
control group:antangonist protocol

Sponsors

Jiangxi Maternal and Child Health Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 38 Years

Inclusion criteria

Inclusion criteria: 1) Have at least one indication for IVF treatment: fallopian tube factor infertility, male factor, ovulation disorder other than polycystic ovary syndrome; 2) Infertility period >=1 year; 3) Ovarian response was normal (basal FSH <10 mIU / ml, AFC 8 to 15, AMH 1.5 to 4.0 ng/ml); 4) 20-38 years of age; 5) Normal menstrual cycle, defined as the menstrual cycle 21-35 days; 6) Body mass index: 18.5-28 Kg/M2; 7) First attempt for IVF / ICSI-ET treatment; 8) Informed consent to this study.

Exclusion criteria

Exclusion criteria: 1) Patients with contraindications to assisted reproductive technology or pregnancy contraindications; 2) Judging by the clinical experience of patients with uterine abnormalities affecting pregnancy, such as uterine malformations (single angle uterus, double angle uterus, double uterus, mediastinal uterus); adenomyosis; uterine fibroids (fibroids greater than 3 cm or within Membrane closely); submucosal uterine fibroids; intrauterine adhesions; endometrial polyps untreated; scar uterine; cervical conization patients; 3) Due to various factors, planned for frozen embryo transfer (such as tubal hydrops, PGD or PGS patients); 4) History of recurrent miscarriage; 5) Polycystic ovary syndrome; 6) Endometriosis III-IV; 7) Unilateral ovarian patients; 8) Chromosome abnormalities on either side of the couple; 9) People with alcoholism, addiction, or drug abuse habits; 10) Patient who participated in other clinical study.

Design outcomes

Primary

MeasureTime frame
live birth rate per initiated cycle;—

Secondary

MeasureTime frame
clinical pregnancy rate;incidence of moderate/severe OHSS;miscarriage rate;live birth rate per embryo transfer cycle;cumulative live birth rate;ectopic pregnancy rate;implantation rate;fertilization rate;good embryo rate;—

Countries

China

Contacts

Public ContactQiongfang Wu
wuqiongfang898@sina.com+86 13970017651

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026